Wireless, Intermittent Monitoring of Right Heart Pressures in HF

CardioMEMS17 enrolled

Overview

The purpose of the trial is to evaluate the wireless monitoring of pulmonary artery pressure using the CardioMEMS HF Pressure Measurement System in adult subjects with NYHA Class III Heart Failure.

The trial is designed to demonstrate that the CardioMEMS Sensor can be positioned in the right or left pulmonary artery, and that Sensor pressure measurements correlate to standardized methods of intra-cardiac pressure measurements post-sensor implant and at the 60 day visit. Safety will be monitored by the occurrence of adverse events throughout the trial.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

NYHA Class III Heart Failure

Interventions

CardioMEMS HF Pressure Measurement SystemDEVICE

Implant sensor into the left or right pulmonary artery. Measure pulmonary artery pressure

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Subject is male or female, at least 18 years of age 2. Subjects of childbearing age who have a negative serum pregnancy test, and at screening have agreed to use a reliable mechanical or hormonal form of conception during the study. 3. Subject has a diagnosis of New York Heart Association (NYHA) Class III HF at screening and at baseline. 4. Subject is able and willing to provide written informed consent or the subject guardian is able and willing to provide informed consent. 5. Subject has life expectancy of 1-2 years. Exclusion Criteria: 1. Subject has unstable medical condition or impairment other than a medical condition associated with HF which would significantly increase the subject's morbidity or mortality risk. 2. Subject is unable to tolerate a right heart catheterization. 3. Subject is planned to undergo a heart transplantation or cardiac surgery within 2 months after enrollment. 4. Subject has permanent indwelling central venous catheter. 5. Subject has history of myocardial infarction (MI), unstable angina, stroke, transient ischemic attack, or intractable arrhythmias within last 2 months. 6. Subject has history of congenital heart disease or prosthetic valve on right side. 7. Subject has unstable hypertension. 8. Subject has a known coagulability disease state. 9. Subject has a known hypersensitivity and/or allergy to aspirin and clopidogrel. 10. Subject has active lung infection or acute pulmonary decompensation. 11. Subject has elevated white blood cell count and signs of infection are evident. 12. Subject has chronic renal insufficiency as defined by serum creatinine of greater than or equal to 2 mg/dl or requirement for dialysis. 13. Subject who is pregnant or lactating or might become pregnant during the duration of the study. 14. Subject who is participating in another therapeutic interventional trial. 15. Subject has other medical, psychological, or social circumstances that may affect the ability to comply with the study requirements or increase risk to the subject.

Locations (4)

Piedmont Hospital

Atlanta, Georgia, United States

Ohio State University Hospital

Columbus, Ohio, United States

Oklahoma Heart Hospital

Oklahoma City, Oklahoma, United States

St Thomas Hospital

Nashville, Tennessee, United States

Outcomes

Primary Outcomes

The primary objective is to evaluate the wireless monitoring of pulmonary artery pressure using the CardioMEMS HF Pressure Measurement System in adult subjects with Class III Heart Failure.

The trial will demonstrate that the CardioMEMS Sensor can be positioned in the right or left pulmonary artery, and the Sensor pulmonary artery pressure measurements correlate to standardized methods of intra-cardiac pressure measurements immediately after deployment of the sensor and at the 60 day follow-up visit. Safety is assessed by monitoring the occurrence of adverse events.

Time frame: after implant of the sensor and at 60 day visit

Secondary Outcomes

To demonstrate the capability of the CardioMEMS HF System to obtain the pressure measurement from the Sensor and transmit the pulmonary artery pressure data to a secure database.

Time frame: after deployment of the sensor and at 60 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.